SeraCare Life Sciences (Nasdaq: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announces the launch of its new Worldwide HIV Performance Panel. SeraCare's Performance Panels are unique, value-added products that enable assay developers, regulators and end-users to evaluate and troubleshoot assays using highly characterized, naturally-occurring plasma samples. This new HIV panel presents a group of HIV positive plasma samples with diverse variants of HIV, allowing efficient evaluation of HIV assays against multiple strains of the virus. SeraCare's Worldwide HIV Performance Panel includes 20 members—17 are HIV-1 positive, covering 10 different subtypes, two are HIV-2 positive and one is negative. Plasma was sourced from Africa, Asia, Europe and Central America and includes rare and difficult to source HIV genotypes.
"SeraCare's newest performance panel demonstrates again our commitment to providing critical, hard-to-find materials that can reduce assay development time and speed regulatory approval for our customers," commented Susan Vogt, President and CEO of SeraCare. "Further, the launch of this panel reflects progress in a key strategic initiative at SeraCare. Our industry-leading portfolio of geographically diverse and carefully pedigreed patient samples is a differentiated asset that further solidifies our leadership role in creating specialized panels for diagnostics development."
Affordability and supply remain critical to the success of long-lasting HIV drug